Important Information for Maravai Lifesciences Holdings, Inc. (MRVI) Investors: Rosen Law Firm Reminds of Class Action Lawsuit Deadline
New York, NY, March 24, 2025 – Rosen Law Firm, a global investor rights law firm, reminds purchasers of Maravai Lifesciences Holdings, Inc. (MRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. The lawsuit alleges that Maravai Lifesciences Holdings and certain of its officers and directors violated the Securities Exchange Act of 1934 by making materially false and misleading statements and/or failing to disclose that: (1) the Company’s financial statements for the fiscal years 2023 and 2024 contained material errors; (2) the Company’s revenue growth was primarily due to acquisitions and not organic growth; and (3) as a result, the Company’s financial statements were not reliable.
Background on Maravai Lifesciences Holdings, Inc.
Maravai Lifesciences Holdings, Inc. is a life sciences company that provides contract development and manufacturing services to the biopharmaceutical industry. The Company offers a range of services, including process development, analytical development, manufacturing, packaging, and labeling. Maravai Lifesciences Holdings operates through its subsidiaries, including Avista Pharma Solutions, Inc., Quotient Sciences, and Maravai Technologies, Inc.
The Class Action Lawsuit
The class action lawsuit was filed in the United States District Court for the District of New Jersey on February 25, 2025, on behalf of purchasers of Maravai Lifesciences Holdings securities during the Class Period. The complaint alleges that defendants made false and misleading statements and/or failed to disclose that: (1) Maravai Lifesciences Holdings’ financial statements for the fiscal years 2023 and 2024 contained material errors; (2) the Company’s revenue growth was primarily due to acquisitions and not organic growth; and (3) as a result, the Company’s financial statements were not reliable. When the true details entered the market, the price of Maravai Lifesciences Holdings’ securities declined significantly.
Impact on MRVI Investors
If you purchased Maravai Lifesciences Holdings securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is May 5, 2025, so it’s important that you contact Rosen Law Firm as soon as possible to discuss your potential recovery options. The securities fraud class action lawsuit seeks to recover damages on behalf of Maravai Lifesciences Holdings investors who lost money as a result of the defendants’ misconduct. The lawsuit aims to hold the defendants accountable for their actions and obtain a court order requiring them to compensate investors for their losses.
Impact on the World
The Maravai Lifesciences Holdings class action lawsuit is significant because it highlights the importance of accurate financial reporting in the life sciences industry. The lawsuit alleges that Maravai Lifesciences Holdings and its executives misrepresented the Company’s financial condition and growth, which can lead to significant consequences for investors and the overall market. This case serves as a reminder for companies to ensure the accuracy of their financial reports and for investors to exercise due diligence when making investment decisions.
Conclusion
If you purchased Maravai Lifesciences Holdings securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is May 5, 2025, so it’s important that you contact Rosen Law Firm as soon as possible to discuss your potential recovery options. The securities fraud class action lawsuit seeks to recover damages on behalf of Maravai Lifesciences Holdings investors who lost money as a result of the defendants’ misconduct. The lawsuit aims to hold the defendants accountable for their actions and obtain a court order requiring them to compensate investors for their losses. The case also serves as a reminder for companies to ensure the accuracy of their financial reports and for investors to exercise due diligence when making investment decisions.
- Rosen Law Firm reminds Maravai Lifesciences Holdings investors of the May 5, 2025 lead plaintiff deadline.
- The lawsuit alleges that Maravai Lifesciences Holdings and certain of its officers and directors violated securities laws.
- The Company’s financial statements for the fiscal years 2023 and 2024 contained material errors.
- The Company’s revenue growth was primarily due to acquisitions and not organic growth.
- Investors who purchased Maravai Lifesciences Holdings securities during the Class Period may be entitled to compensation.
- The lawsuit aims to hold the defendants accountable for their actions and obtain a court order requiring them to compensate investors for their losses.
- The case serves as a reminder for companies to ensure the accuracy of their financial reports and for investors to exercise due diligence when making investment decisions.
